Vincent J L
Université Libre de Bruxelles, Brussels, Belgium.
Crit Care. 2000;4 Suppl 2(Suppl 2):S1-2. doi: 10.1186/cc964. Epub 2000 Oct 13.
Fluid management strategies need to be guided by an understanding of the pathophysiologic mechanisms underlying fluid imbalance. In the hypovolaemic patient, reduced circulating blood volume and venous return and, in severe cases, altered tissue perfusion may initiate a cascade of pathophysiologic processes culminating in multiple organ failure. The objectives of fluid management are to maintain adequate blood pressure, tissue oxygenation and intravascular fluid volume. Both crystalloids and colloids can be useful for these purposes. In the hypovolaemic patient with normal pulmonary function, the use of colloids to maintain colloid osmotic pressure can limit the development of peripheral as well as pulmonary oedema. However, choice of fluid is less important in states of increased lung capillary permeability. Further evidence is needed to broaden understanding of the optimal roles for particular fluid management strategies. Experimental models can make an important contribution in gathering such evidence. Rigorous pharmacoeconomic studies are also needed to define the benefits and costs of differing fluid regimens.
液体管理策略需要以对液体失衡背后病理生理机制的理解为指导。在低血容量患者中,循环血容量和静脉回流减少,在严重情况下,组织灌注改变可能引发一系列病理生理过程,最终导致多器官功能衰竭。液体管理的目标是维持足够的血压、组织氧合和血管内容量。晶体液和胶体液都可用于这些目的。在肺功能正常的低血容量患者中,使用胶体液维持胶体渗透压可限制外周及肺水肿的发展。然而,在肺毛细血管通透性增加的状态下,液体的选择不那么重要。需要进一步的证据来拓宽对特定液体管理策略最佳作用的理解。实验模型可在收集此类证据方面做出重要贡献。还需要进行严格的药物经济学研究,以确定不同液体方案的益处和成本。